Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by John Gaetano
Benefit–risk Assessment of New and Emerging Treatments for Hepatitis C: Focus on Simeprevir and Sofosbuvir
Drug, Healthcare and Patient Safety
Health Policy
Pharmacology
Related publications
New Agents for the Treatment of Hepatitis C Virus &Ndash; Focus on Telaprevir
Virus Adaptation and Treatment
Virology
Infectious Diseases
Immunology
Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis
Hepatology
Medicine
Hepatology
Cost-Effectiveness of Sofosbuvir-Based Treatments for Chronic Hepatitis C in the US
BMC Gastroenterology
Medicine
Gastroenterology
Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in Treatment-Naïve Hepatitis C Virus Genotype 1-Infected Patients Without Cirrhosis Treated With a Simeprevir/Sofosbuvir/Ledipasvir Regimen
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Benefit-Risk Assessment for Sofosbuvir/Velpatasvir/Voxilaprevir Based on Patient Population and HCV Genotype: FDA's Evaluation
Hepatology
Medicine
Hepatology
Ledipasvir and Sofosbuvir for Recurrent Hepatitis C After Liver Transplantation
BioScience Trends
Biochemistry
Health
Medicine
Genetics
Molecular Biology
Cost Effectiveness Analysis of Sofosbuvir and Ledipasvir/Sofosbuvir in Hepatitis C Virus (HCV) Patients
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
JAMA - Journal of the American Medical Association
Medicine
Emerging Small-Molecule Treatments for Multiple Sclerosis: Focus on B Cells
F1000Research
Genetics
Molecular Biology
Pharmacology
Biochemistry
Microbiology
Immunology
Medicine
Toxicology
Pharmaceutics
